Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 10/20 | 0.80 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | MAX | P61244 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346702 | 1.00 | MYC (0.80) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346013 | 0.84 | MYC (0.77) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346014 | 0.84 | MYC (0.77) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346080 | 0.84 | MYC (0.70) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346081 | 0.84 | MYC (0.70) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346448 | 0.84 | MYC (0.69) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346449 | 0.84 | MYC (0.69) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346075 | 0.83 | MYC (0.75) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL346076 | 0.83 | MYC (0.75) | MYCPPARGNCOA1NCOA3MAX | |
| SCHEMBL17927296 | 0.80 | MYC (0.70) | MYCPPARGMAXRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637556-B2 | Linked Myc-max small molecule inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | MYC, MAX, MYCBP | MYC 1/4885PPARG 3040/4885NCOA1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.